Quantcast
StreetInsider.com streetinsider.com 26 Jan, 2023 02:30 am

Genelux Corporation Announces Pricing of Initial Public Offering

25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux” or “the Company”), a clinical-stage immunotherapy company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types, today announced the pricing of its initial public offering of 2,500,000 shares of its common stock at a price to the public of $6.About Genelux Corporation Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.4912 p Source: Genelux Corporation Serious News for Serious Traders!In addition, Genelux has granted the underwriters a 30-day option to purchase up to an additional 375,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions.

Forward-Looking Statements This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering.Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Genelux, including those set forth in the Risk Factors section of Genelux’s registration statement for the initial public offering filed with the SEC.

Read full story at streetinsider.com